These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23672220)

  • 1. Efficacy and safety of acarbose chewable tablet in patients with type 2 diabetes: a multicentre, randomized, double-blinded, double-dummy positive controlled trial.
    Wu QL; Liu YP; Lu JM; Wang CJ; Yang T; Dong JX; Li CJ; Ma JH; Xue YM; Sun RH; Wei D; Tian HM
    J Evid Based Med; 2012 Aug; 5(3):134-8. PubMed ID: 23672220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas.
    Lin BJ; Wu HP; Huang HS; Juang JH; Sison A; bin Abdul Kadir DK; Cho CG; Sridama W;
    J Diabetes Complications; 2003; 17(4):179-85. PubMed ID: 12810240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes.
    Jayaram S; Hariharan RS; Madhavan R; Periyandavar I; Samra SS
    J Assoc Physicians India; 2010 Nov; 58():679-82, 687. PubMed ID: 21510461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone.
    Feinböck C; Luger A; Klingler A; Egger T; Bielesz GK; Winkler F; Siebenhofer A; Grossschädl F; Frank E; Irsigler K;
    Diabetes Nutr Metab; 2003 Aug; 16(4):214-21. PubMed ID: 14768770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone.
    Wang W; Ning G; Ma J; Liu X; Zheng S; Wu F; Xu L; O'Neill EA; Fujita KP; Engel SS; Kaufman KD; Shankar RR
    Curr Med Res Opin; 2017 Apr; 33(4):693-699. PubMed ID: 28035868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin.
    Phillips P; Karrasch J; Scott R; Wilson D; Moses R
    Diabetes Care; 2003 Feb; 26(2):269-73. PubMed ID: 12547847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group.
    Chan JC; Chan KW; Ho LL; Fuh MM; Horn LC; Sheaves R; Panelo AA; Kim DK; Embong M
    Diabetes Care; 1998 Jul; 21(7):1058-61. PubMed ID: 9653595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes.
    Coniff RF; Shapiro JA; Seaton TB; Hoogwerf BJ; Hunt JA
    Diabetes Care; 1995 Jul; 18(7):928-32. PubMed ID: 7555551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients.
    Vichayanrat A; Ploybutr S; Tunlakit M; Watanakejorn P
    Diabetes Res Clin Pract; 2002 Feb; 55(2):99-103. PubMed ID: 11796175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study.
    Halimi S; Le Berre MA; Grangé V
    Diabetes Res Clin Pract; 2000 Sep; 50(1):49-56. PubMed ID: 10936668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycemic variability in insulin treated type 2 diabetes with well-controlled hemoglobin A1c and its response to further treatment with acarbose.
    Su JB; Wang XQ; Chen JF; Wu G; Jin Y
    Chin Med J (Engl); 2011 Jan; 124(1):144-7. PubMed ID: 21362322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial.
    Qu L; Liang X; Tian G; Zhang G; Wu Q; Huang X; Cui Y; Liu Y; Shen Z; Xiao C; Qin Y; Miao H; Zhang Y; Li Z; Ye S; Zhang X; Yang J; Cao G; Li Y; Yang G; Hu J; Wang X; Li Z; Li Y; Zhang X; Zhang G; Chen L; Hua W; Yu M; Lu C; Zhang X; Jiang H
    Diabetes Care; 2021 Jun; 44(6):1324-1333. PubMed ID: 33832957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study.
    Mertes G
    Diabetes Res Clin Pract; 2001 Jun; 52(3):193-204. PubMed ID: 11323089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial.
    Yang W; Liu J; Shan Z; Tian H; Zhou Z; Ji Q; Weng J; Jia W; Lu J; Liu J; Xu Y; Yang Z; Chen W
    Lancet Diabetes Endocrinol; 2014 Jan; 2(1):46-55. PubMed ID: 24622668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity.
    Sun W; Zeng C; Liao L; Chen J; Wang Y
    Curr Med Res Opin; 2016 Aug; 32(8):1389-96. PubMed ID: 27052634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.
    Kelley DE; Bidot P; Freedman Z; Haag B; Podlecki D; Rendell M; Schimel D; Weiss S; Taylor T; Krol A; Magner J
    Diabetes Care; 1998 Dec; 21(12):2056-61. PubMed ID: 9839094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acarbose treatment does not change the habitual diet of patients with Type 2 diabetes mellitus. The Finnish Acargbos Study Group.
    Lindström J; Tuomilehto J; Spengler M
    Diabet Med; 2000 Jan; 17(1):20-5. PubMed ID: 10691155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
    Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
    Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A multicenter randomized controlled clinical trial on blood glucose lowering effects of domestic Acarbose (capsule) in type 2 diabetic patients].
    Ran XW; Zhang DC; Tian HM; Chen P; Pu L; Li WD
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Nov; 38(6):1021-4. PubMed ID: 18095612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.